National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 52325 [2015-21378]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 167 / Friday, August 28, 2015 / Notices
Opportunity on (301) 458–4EEO (4336)
as soon as possible.
Dated: August 24, 2015.
James Scanlon,
Deputy Assistant Secretary for Planning and
Evaluation (Science and Data Policy), Office
of the Assistant Secretary for Planning and
Evaluation.
[FR Doc. 2015–21328 Filed 8–27–15; 8:45 am]
BILLING CODE 4151–05–P
Bethesda, MD 20899823, (240) 669–5062,
wurstera@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: August 25, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–21378 Filed 8–27–15; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
National Institutes of Health
Lhorne on DSK5TPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Implementation (R01).
Date: September 22, 2015.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Room
3G33, 5601 Fishers Lane, Rockville, MD
20892, (Telephone Conference Call).
Contact Person: Andrea L Wurster, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G33B, National Institutes of Health,
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20899823, (240) 669–5062,
wurstera@mail.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Planning Grant (R34).
Date: September 25, 2015.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Room
3G33, 5601 Fishers Lane, Rockville, MD
20892, (Telephone Conference Call).
Contact Person: Andrea L Wurster, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G33B, National Institutes of Health,
NIAID, 5601 Fishers Lane, MSC 9823,
VerDate Sep<11>2014
14:19 Aug 27, 2015
Jkt 235001
Proposed Collection; 60-day Comment
Request: A Multi-Center International
Hospital-Based Case-Control Study of
Lymphoma in Asia (AsiaLymph) (NCI)
In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Cancer Institute, the National
Institutes of Health (NIH) will publish
periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Written comments and/or suggestions
from the public and affected agencies
are invited to address one or more of the
following points: (1) Whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
The quality, utility, and clarity of the
information to be collected; and (4)
Minimize the burden of the collection of
information on those who are to
respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To Submit Comments and for Further
Information: To obtain a copy of the
data collection plans and instruments,
submit comments in writing, or request
more information on the proposed
project, contact: Nathaniel Rothman,
Senior Investigator, Division of Cancer
Epidemiology and Genetics, 9609
Medical Center Drive, MSC 9776, Room
6E134, Bethesda, Maryland 20892 or
call non-toll-free number (240) 276–
7169 or Email your request, including
SUMMARY:
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
52325
your address to: rothmann@
mail.nih.gov. Formal requests for
additional plans and instruments must
be requested in writing.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Proposed Collection: A Multi-Center
International Hospital-Based CaseControl Study of Lymphoma in Asia
(AsiaLymph) (NCI), 0925–0654,
Expiration Date 10/31/2015–REVISION,
National Institutes of Health (NIH).
Need and Use of Information
Collection: Incidence rates of certain
lymphomas have increased in the
United States and in many other parts
of the world. The contribution of
environmental, occupational, and
genetic factors to the cause of
lymphoma and leukemia has generated
a series of novel findings from
epidemiological studies conducted in
the United States that have attempted to
explain this increase. However, none of
the chemical associations have been
conclusively established and the
identification of the key, functional
alleles in gene regions associated with
risk of lymphoma requires further
elucidation. Further, the ability to
follow-up, confirm, and extend these
observations in the United States is
limited by the low prevalence and
limited range of several important
chemical and viral exposures and the
high to complete linkage disequilibrium
among key candidate genetic loci in
Western populations. To optimize the
ability to build on and clarify these
findings, it is necessary to investigate
populations that differ from those in the
West in both exposure patterns and
underlying genetic structure. A
multidisciplinary case-control study of
lymphoma in Asia, where lymphoma
rates have also risen, provides an
opportunity to replicate and extend
recent and novel observations made in
studies in the West in a population that
is distinctly different with regard to
patterns of key risk factors, including
range of exposures, prevalence of
exposures, correlations between
exposures, and variation in gene regions
of particular interest. It will also
improve the ability to understand the
causes of certain types of rare
lymphoma tumors in the United States
that occur at much higher rates in Asia.
As such, AsiaLymph will confirm and
extend previous findings and yield
novel insights into the causes of
lymphoma and leukemia in both Asia
and in the United States. The major
postulated risk factors for evaluation in
this study are chemical exposures (i.e.,
E:\FR\FM\28AUN1.SGM
28AUN1
]]>Agencies
[Federal Register Volume 80, Number 167 (Friday, August 28, 2015)]
[Notices]
[Page 52325]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-21378]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation
(R01).
Date: September 22, 2015.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Room 3G33, 5601 Fishers
Lane, Rockville, MD 20892, (Telephone Conference Call).
Contact Person: Andrea L Wurster, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, Room 3G33B, National Institutes of Health, NIAID, 5601
Fishers Lane, MSC 9823, Bethesda, MD 20899823, (240) 669-5062,
wurstera@mail.nih.gov.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Clinical Trial Planning Grant
(R34).
Date: September 25, 2015.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Room 3G33, 5601 Fishers
Lane, Rockville, MD 20892, (Telephone Conference Call).
Contact Person: Andrea L Wurster, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, Room 3G33B, National Institutes of Health, NIAID, 5601
Fishers Lane, MSC 9823, Bethesda, MD 20899823, (240) 669-5062,
wurstera@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: August 25, 2015.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-21378 Filed 8-27-15; 8:45 am]
BILLING CODE 4140-01-P
